88 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
for a majority of commercially covered lives for ZURZUVAE in the treatment of women with postpartum depression (PPD) without step therapy or complex prior … and expect formulary discussions to continue over the course of 2024.
In the first quarter of 2024, the majority of prescriptions were covered
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
17 Apr 24
Regulation FD Disclosure
6:35am
, and there were no new safety signals observed. A total of 48 participants experienced treatment emergent adverse events (TEAEs). The vast majority of TEAES
8-K
EX-99.1
x3kb9 lsh
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
SC TO-I
EX-99
kums0d1x7c16o
23 Jan 24
Issuer tender offer statement
8:13am
SC TO-I
EX-99
pc8k4pr0zp
23 Jan 24
Issuer tender offer statement
8:13am
PRE 14A
gyu19ahk2elbgo4jq
8 Dec 23
Preliminary proxy
8:30am
424B5
ttdgf
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-3.1
mi0l yf6raohv
16 Jun 23
Departure of Directors or Certain Officers
4:06pm